Absci Corp (ABSI) is a cutting-edge biotechnology company that utilizes an advanced AI-driven biology platform to revolutionize the drug discovery process. By facilitating the rapid generation of high-quality proteins and therapeutic candidates, Absci significantly shortens development timelines and lowers costs, making it a key player in the biopharmaceutical industry. The company actively collaborates with a diverse array of partners to create and manufacture next-generation therapies, underscoring its commitment to innovation and precision. With a robust pipeline of collaborations and proprietary programs, Absci is poised to deliver meaningful advancements in modern medicine and address critical healthcare challenges.
| Revenue (TTM) | $1.84M |
| Gross Profit (TTM) | $-81.79M |
| EBITDA | $-116.44M |
| Operating Margin | -14347.00% |
| Return on Equity | -63.90% |
| Return on Assets | -37.30% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $1.11 |
| Price-to-Book | 4.62 |
| Price-to-Sales (TTM) | 433.07 |
| EV/Revenue | 367.01 |
| EV/EBITDA | -0.39 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -81.80% |
| Shares Outstanding | $155.91M |
| Float | $146.16M |
| % Insiders | 13.04% |
| % Institutions | 78.85% |
Volatility is currently contracting